Cargando…
Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
INTRODUCTION: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iG...
Autores principales: | McCrimmon, Rory J., Falla, Edel, Sha, Jo Zhou, Alsaleh, Abdul Jabbar Omar, Lew, Elisheva, Hudson, Richard, Baxter, Mike, Palmer, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586275/ https://www.ncbi.nlm.nih.gov/pubmed/34714523 http://dx.doi.org/10.1007/s13300-021-01159-y |
Ejemplares similares
-
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
por: McCrimmon, Rory J., et al.
Publicado: (2022) -
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
por: Shao, Hui, et al.
Publicado: (2022) -
Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
por: McCrimmon, Rory J., et al.
Publicado: (2021) -
Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
por: Polonsky, William H., et al.
Publicado: (2022) -
Advancing Therapy in Suboptimally Controlled Basal
Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus
Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
por: Rosenstock, Julio, et al.
Publicado: (2021)